It was the guy on the grassy knoll. Please. Enough buying for institutions to lock-up shareholder approval on deal, that is for sure.
Done deal. Board approves, and Ladenburg certainly has shareholder backing, with these types of players involved. I sold my last 1/3 at .45 and that was probably a bad trade, but thank God for those pre-market upticks.
From here on out, it is a liver disease company. Bottom line. The issue I have is the very small end markets for these drugs, in terms of number afflicted, but they can probably charge a ton if the treatment works.
Better ideas out there, IMO. GLTA.
Sold 2/3 in the pre or I would be scratching my head too. Niche pipeline. Prob a buy down here intraday but a lot of peeps underwater from the open. I'm out hasta.
Ladenburg also needs to build institutional support for this deal. Should be willing buyers. Ccall up next.
Lol. Nothing to get so worked up about. The link is simply a very brief description of the new CEOs background and synopsis of the new company that was acquired via reverse merger. Shouldn't be a surprise to anyone who understands the potential outcomes. Fyi